Literature DB >> 19407258

Role of calcitonin gene-related peptide (CGRP) in ovine burn and smoke inhalation injury.

Matthias Lange1, Perenlei Enkhbaatar, Daniel L Traber, Robert A Cox, Sam Jacob, Babu P Mathew, Atsumori Hamahata, Lillian D Traber, David N Herndon, Hal K Hawkins.   

Abstract

Concomitant smoke inhalation trauma in burn patients is a serious medical problem. Previous investigations in our sheep model revealed that these injuries lead to significant airway hyperemia, enhanced pulmonary fluid extravasation, and severely impaired pulmonary function. However, the pathophysiological mechanisms are still not fully understood. The lung is innervated by sensory nerves containing peptides such as substance P and calcitonin gene-related peptide. Noxious stimuli in the airways can induce a neurogenic inflammatory response, which has previously been implicated in several airway diseases. Calcitonin gene-related peptide is known to be a potent vasodilator. We hypothesized that calcitonin gene-related peptide is also a mediator of the pulmonary reaction to toxic smoke and planned experiments to evaluate its role in this model. We tested the effects of pretreatment with a specific antagonist of the major receptor for calcitonin gene-related peptide (BIBN4096BS; 32 microg/kg, followed by continuous infusion of 6.4 microg.kg(-1).h(-1)) until the animal was killed 48 h after injury in an established ovine model of burn (40% total body surface, third degree) and smoke inhalation (48 breaths, <40 degrees C) injury. In treated animals (n = 7), the injury-related increases in tracheal blood flow and lung lymph flow were significantly attenuated compared with untreated controls (n = 5). Furthermore, the treatment significantly attenuated abnormalities in respiratory gas exchange. The data suggest that calcitonin gene-related peptide contributes to early airway hyperemia, transvascular fluid flux, and respiratory malfunction following ovine burn and smoke inhalation injury. Future studies will be needed to clarify the potential therapeutic benefit for patients with this injury.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19407258      PMCID: PMC2711784          DOI: 10.1152/japplphysiol.00094.2009

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  50 in total

1.  Vagally mediated vasodilatation by motor and sensory nerves in the tracheal and bronchial circulation of the pig.

Authors:  R Matran; K Alving; C R Martling; J S Lacroix; J M Lundberg
Journal:  Acta Physiol Scand       Date:  1989-01

Review 2.  The role of endogenous lung neuropeptides in regulation of the pulmonary circulation.

Authors:  I M Keith
Journal:  Physiol Res       Date:  2000       Impact factor: 1.881

3.  Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist.

Authors:  H Doods; G Hallermayer; D Wu; M Entzeroth; K Rudolf; W Engel; W Eberlein
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

4.  Efficacy of the non-peptide CGRP receptor antagonist BIBN4096BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment.

Authors:  M J Moreno; R Abounader; E Hébert; H Doods; E Hamel
Journal:  Neuropharmacology       Date:  2002-03       Impact factor: 5.250

Review 5.  Neuropeptides and their receptors: innovative science providing novel therapeutic targets.

Authors:  Susan D Brain; Helen M Cox
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

Review 6.  Calcitonin gene-related peptide: vasoactive effects and potential therapeutic role.

Authors:  S D Brain; H Cambridge
Journal:  Gen Pharmacol       Date:  1996-06

7.  Bronchoprotector properties of calcitonin gene-related peptide in guinea pig and human airways. Effect of pulmonary inflammation.

Authors:  A Cadieux; N P Monast; F Pomerleau; A Fournier; C Lanoue
Journal:  Am J Respir Crit Care Med       Date:  1999-01       Impact factor: 21.405

8.  The calcitonin gene-related peptide (CGRP) receptor antagonist BIBN4096BS blocks CGRP and adrenomedullin vasoactive responses in the microvasculature.

Authors:  A D Grant; C W Tam; Z Lazar; M K Shih; S D Brain
Journal:  Br J Pharmacol       Date:  2004-07-05       Impact factor: 8.739

9.  Sensory nerves containing tachykinins and CGRP in the lower airways. Functional implications for bronchoconstriction, vasodilatation and protein extravasation.

Authors:  C R Martling
Journal:  Acta Physiol Scand Suppl       Date:  1987

Review 10.  The blood-brain barrier in migraine treatment.

Authors:  L Edvinsson; P Tfelt-Hansen
Journal:  Cephalalgia       Date:  2008-08-22       Impact factor: 6.292

View more
  12 in total

1.  Beneficial pulmonary effects of a metalloporphyrinic peroxynitrite decomposition catalyst in burn and smoke inhalation injury.

Authors:  Matthias Lange; Csaba Szabo; Perenlei Enkhbaatar; Rhykka Connelly; Eszter Horvath; Atsumori Hamahata; Robert A Cox; Aimalohi Esechie; Yoshimitsu Nakano; Lillian D Traber; David N Herndon; Daniel L Traber
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-11-12       Impact factor: 5.464

Review 2.  Inhalation Injury in the Burned Patient.

Authors:  Guillermo Foncerrada; Derek M Culnan; Karel D Capek; Sagrario González-Trejo; Janos Cambiaso-Daniel; Lee C Woodson; David N Herndon; Celeste C Finnerty; Jong O Lee
Journal:  Ann Plast Surg       Date:  2018-03       Impact factor: 1.539

3.  Preclinical evaluation of epinephrine nebulization to reduce airway hyperemia and improve oxygenation after smoke inhalation injury.

Authors:  Matthias Lange; Atsumori Hamahata; Daniel L Traber; Robert A Cox; Gabriela A Kulp; Yoshimitsu Nakano; Lillian D Traber; David N Herndon; Perenlei Enkhbaatar
Journal:  Crit Care Med       Date:  2011-04       Impact factor: 7.598

4.  Beneficial effects of concomitant neuronal and inducible nitric oxide synthase inhibition in ovine burn and inhalation injury.

Authors:  Matthias Lange; Atsumori Hamahata; Perenlei Enkhbaatar; Robert A Cox; Yoshimitsu Nakano; Martin Westphal; Lillian D Traber; David N Herndon; Daniel L Traber
Journal:  Shock       Date:  2011-06       Impact factor: 3.454

5.  Molecular biological effects of selective neuronal nitric oxide synthase inhibition in ovine lung injury.

Authors:  Fiona D Saunders; Martin Westphal; Perenlei Enkhbaatar; Jianpu Wang; Konrad Pazdrak; Yoshimitsu Nakano; Atsumori Hamahata; Collette C Jonkam; Matthias Lange; Rhykka L Connelly; Gabriela A Kulp; Robert A Cox; Hal K Hawkins; Frank C Schmalstieg; Eszter Horvath; Csaba Szabo; Lillian D Traber; Elbert Whorton; David N Herndon; Daniel L Traber
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-12-04       Impact factor: 5.464

Review 6.  Calcitonin gene-related peptide: physiology and pathophysiology.

Authors:  F A Russell; R King; S-J Smillie; X Kodji; S D Brain
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

Review 7.  The Role of Neurogenic Inflammation in Blood-Brain Barrier Disruption and Development of Cerebral Oedema Following Acute Central Nervous System (CNS) Injury.

Authors:  Annabel J Sorby-Adams; Amanda M Marcoionni; Eden R Dempsey; Joshua A Woenig; Renée J Turner
Journal:  Int J Mol Sci       Date:  2017-08-17       Impact factor: 5.923

Review 8.  Pathophysiology, research challenges, and clinical management of smoke inhalation injury.

Authors:  Perenlei Enkhbaatar; Basil A Pruitt; Oscar Suman; Ronald Mlcak; Steven E Wolf; Hiroyuki Sakurai; David N Herndon
Journal:  Lancet       Date:  2016-10-01       Impact factor: 79.321

9.  Difficulties in modelling ARDS (2017 Grover Conference Series).

Authors:  Stefan Uhlig; Wolfgang M Kuebler
Journal:  Pulm Circ       Date:  2018-03-09       Impact factor: 3.017

Review 10.  Diagnosis and management of inhalation injury: an updated review.

Authors:  Patrick F Walker; Michelle F Buehner; Leslie A Wood; Nathan L Boyer; Ian R Driscoll; Jonathan B Lundy; Leopoldo C Cancio; Kevin K Chung
Journal:  Crit Care       Date:  2015-10-28       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.